Development of new anti-cancer drugs
Tóm tắt
In the first award lecture of the European Society of Medical Oncology (ESMO) the topic of new drug development and the role of the European Organization for Research and Treatment of Cancer (EORTC) was highlighted. New aspects in each of the drug development steps are discussed: acquisition, screening, formulation, toxicology and phase I studies. In the search for new compounds to treat human solid tumors it is proposed to use human tumors as xenografts in primary screening. Phenomena related to doxorubicin resistance are presented together with a new approach to circumvent this in the clinic. The value of biochemical modulation is discussed, exemplified by the combination of 5-fluorouracil and uridine. The complexity of the biological response modifiers and the importance of evaluating them adequately in the clinic is stressed. The EORTC has recently decided on requirements for the minimum toxicology for phase I trials of a new cytostatic drug in order to ensure safe and rapid evaluation of new anti-cancer compounds. The therapeutic intents of phase I studies are questionable and therefore the main goals of these studies to be reached quickly; possibly supported by a pharmacokinetic rational.
Tài liệu tham khảo
Venditti J M: Preclinical drug development: rationale and methods.Seminars in Oncology 8, 349 (1981).
Golding A, Venditti J M, MacDonald J S, Muggia F M, Henney J E and DeVita V T: Current results of the screening program at the division of cancer treatment, National Cancer Institute.Eur J Cancer 17, 129 (1981).
NCI planning to switch drug development emphasis from compound to human cancer oriented strategy.Cancer Lett 10, 1–3 (1984).
Shoemaker R H, Wolpert-DeFilippes M K, Kern D H, Lieber M M, Makuch R W, Melnick N R, Miller W T, Salmon S E, Simon R M, Venditti J M and Von Hoff D D: Application of a human tumor colony-forming assay to new drug screening.Cancer Res 45 2145 (1985).
Martin D S, Balis M E, Frei E, Goldin A, Heppner G H, Holland J F, Houghton J A, Houghton P J, Johnson R K, Mittelman A, Rustum Y, Sawyer R C, Schmid F A, Stolfi R L, Young C W: The role of murine tumor models in cancer treatment research. Presented at the Work Shop on Disease Oriented Antitumor Drug Discovery and Development, NCI, Bethesda, MD, U.S.A., 9–10 January (1985).
DCT Board approves new screening program, natural product concepts.Cancer Lett 11, 4–6 (1985)
Steel G G, Courtenay V D, Peckham M J: The response to chemotherapy of a variety of human tumor xenografts.Br J Cancer 47, 1 (1983).
Osieka R: Studies on drug resistance in a human melanoma xenograft system.Cancer Treat Rev 11 (A), 85 (1984).
Fiebig H H, Schuchhartdt C, Henss H, Fiedler L, Loehr G W: Comparison of tumor response in nude mice and in the patients.Behring Inst Mitt 74, 343 (1984).
Shorthouse A J, Jones J M, Steel G G, Peckham M J: Experimental combination and single-agent chemotherapy in human lung-tumour xenografts.Br J Cancer 46, 35 (1982).
Bailey M J, Gazet J-C, Smith I E, Steel G G: Chemotherapy of human breast-carcinoma xenografts.Br J Cancer 42, 530 (1980).
Nowak K, Peckham M J, Steel G G: Variation in response of colorectal carcinoma to chemotherapy.Br J Cancer 37, 576 (1978).
Braakhuis B J M, Snow G B: Current therapy series (In press)
Boven E: Human ovarian cancer xenografts in nude mice. Application of a new model in the selection of novel agents for ovarian cancer. Rodopi, Amsterdam (1986).
Giovanella B C, Stehlin J S, Shepard R C, Williams L J: Correlation between response to chemotherapy of human tumors in patients and in nude mice.Cancer 52, 1146 (1983).
Boven E, Vijgh W J F van der, Nauta M M, Schlüper H M M, Pinedo H M: Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.Cancer Res 45, 86 (1985).
Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y: Circumvention of vincristine and adriamycin resistancein vitro andin vivo by calcium influx blockers.Cancer Res 43, 2905 (1983).
Peters G J, van Dijk J, van Groeningen C, Laurensse E J, Leyva A, Lankelma J, Pinedo H M: Toxicity and antitumor effects of 5-fluorouracil and its rescue by uridine, in:Purine and Pyrimidine Metabolism in Man, V, Part B, 121 (1986).
Martin D S, Stolfi F L, Sawyer R V, Spiegelman F, Jung C W: High dose 5-fluorouracil with delayed uridine rescue in mice.Cancer Res 42, 3964 (1982)
Kok R M, De Jong A P J M, Van Groeningeu C J, Peters G J, Lankelma J: Highly sensitive determination of 5-fluorouracil in human plasma by capillary gas chromatography and negative ion chemical ionization mass spectometry.J Chromatogr 343, 59 (1985).
Oldham R K, Thurman B G, Talmadge J E, Stevenson H C, Foon K A: Lymphokines, monoclonal antibodies, and other biological response modifiers in the treatment of cancer.Cancer 54, 2795 (1984).
Colcher D, Zalutsky M, Kaplan W, Kufe D, Austin F, Schlom J: Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody.Cancer Res 43, 736 (1983).
Meeker T, Lowder J, Cleary M L, Stewart S, Warnke R, Sklar J, Levy R: Emergence of idiotype variants during treatment of B-cell lymphoma with antiidiotype antibodies.New Engl J Med 312, 1658 (1985).
Rozencweig M, Von Hoff D D, Staquet M J, Guarino A M, Schein P S, Penta J S, Golding A, Muggia F, DeVita V T, Freireich E J: Animal toxicology for early clinical trials with anticancer agents.Cancer Clin Trials 4, 21 (1981).
Lelieveld P, Velzen D van, Vijgh W J F van der, Klein I, Pinedo H M, Putten L M van: Toxicology of 5 platinum derivatives in dogs.Invest New Drugs 2, 101 (1984).
Collins J M, Zaharko D S, Dedrick R L, Chabner B A: Potential roles for preclinical pharmacology in phase I trials.Cancer Treatment Rep 70, 73 (1986).